Previous Close | 4.5000 |
Open | 4.5900 |
Bid | 4.5800 x 1000 |
Ask | 4.6200 x 1000 |
Day's Range | 4.5000 - 4.8500 |
52 Week Range | 2.8300 - 17.6000 |
Volume | |
Avg. Volume | 288,730 |
Market Cap | 174.921M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 5.15 |
EPS (TTM) | 0.8900 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for IKNA
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, will participate in a panel discussion at the William Blair Biotech Focus Conference, taking place Wednesday, July 13, 2022 in New York, NY. Management will also be conducting one-on-one investor meetings at the conference. Details on the panel ca
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM). Fast Track designation granted by FDA facilitates the de
We can readily understand why investors are attracted to unprofitable companies. For example, although...